KINASE INHIBITORS
Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects
Updated results from the ASPEN trial of second-generation Bruton kinase inhibitor (BTK) zanubrutinib—presented during the Virtual 2020 ASCO Annual Meeting—demonstrated decreased occurrence of atrial fibrillation/flutter of any grade and hypertension among patients with MYD88-positive Waldenström macroglobulinemia compared with ibrutinib, adding to the growing body of evidence that second-generation BTKs may have fewer off-target effects compared with first-generation BTKs.
American Journal of Managed Care
